Literature DB >> 32865681

Mesenchymal stem cells ameliorate oxidative stress, inflammation, and hepatic fibrosis via Nrf2/HO-1 signaling pathway in rats.

Sally M Khadrawy1, Hanaa M Mohamed1, Ayman M Mahmoud2.   

Abstract

Liver fibrosis occurs in most types of chronic liver diseases and can develop into cirrhosis and liver failure. Bone marrow-derived mesenchymal stem cells (BMSCs) showed promising effects in the treatment of fibrosis. This study evaluated the possible role of Nrf2/HO-1 signaling in the ameliorative effect of BMSCs against carbon tetrachloride (CCl4)-induced liver fibrosis, oxidative stress, and inflammation in rats. Hepatic fibrosis was induced by subcutaneous injection of CCl4 twice per week for 6 consecutive weeks and rat BMSCs were administered intravenously. After 4 weeks, the rats were sacrificed, and samples were collected for analysis. CCl4-intoxicated rats showed elevated serum transaminases, ALP, γGT, bilirubin and pro-inflammatory cytokines, and decreased albumin. Hepatic NF-κB p65 and malondialdehyde (MDA) were significantly increased, and cellular antioxidants were decreased in CCl4-intoxicated rats. BMSCs ameliorated liver function markers, suppressed MDA, NF-κB p65, and inflammatory cytokines, and enhanced antioxidants in the liver of CCl4-intoxicated rats. BMSCs were engrafted within the liver tissue and prevented histological alterations and collagen accumulation induced by CCl4. In addition, BMSCs upregulated hepatic Nrf2 and HO-1 expression in CCl4-intoxicated rats. In conclusion, this study provides evidence that BMSCs suppress oxidative stress, inflammation, and liver fibrosis through a mechanism involving activation of the Nrf2/HO-1 signaling.

Entities:  

Keywords:  Cell therapy; Liver fibrosis; Nrf2; Oxidative stress; Stem cells

Year:  2020        PMID: 32865681     DOI: 10.1007/s11356-020-10637-y

Source DB:  PubMed          Journal:  Environ Sci Pollut Res Int        ISSN: 0944-1344            Impact factor:   4.223


  6 in total

1.  Extracellular Vesicles from miR-148a-5p-Enriched Bone Marrow Mesenchymal Stem Cells Relieve Hepatic Fibrosis by Targeting Smad4.

Authors:  Ji Xuan; Huabin Xu; Hui Li; Desheng Chen; Yuping Qiu; Xi Chen; Mei Shao; Xianming Xia
Journal:  Mol Biotechnol       Date:  2022-01-10       Impact factor: 2.695

Review 2.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 3.  Adult stem cell transplantation combined with conventional therapy for the treatment of end-stage liver disease: a systematic review and meta-analysis.

Authors:  Chen-Hui Zhu; Dian-Han Zhang; Chen-Wei Zhu; Jing Xu; Chuan-Long Guo; Xiang-Gen Wu; Qi-Long Cao; Guo-Hu Di
Journal:  Stem Cell Res Ther       Date:  2021-10-30       Impact factor: 6.832

4.  Upregulation of Nrf2/HO-1 Signaling and Attenuation of Oxidative Stress, Inflammation, and Cell Death Mediate the Protective Effect of Apigenin against Cyclophosphamide Hepatotoxicity.

Authors:  Wesam Al-Amarat; Mohammad H Abukhalil; Reem S Alruhaimi; Haifa A Alqhtani; Nouf Aldawood; Manal A Alfwuaires; Osama Y Althunibat; Saleem H Aladaileh; Abdulmohsen I Algefare; Abdulkareem A Alanezi; Ali M AbouEl-Ezz; Ahmad F Ahmeda; Ayman M Mahmoud
Journal:  Metabolites       Date:  2022-07-14

Review 5.  Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control.

Authors:  Yun Gao; Xiushan Yin; Xiaomeng Ren
Journal:  Stem Cells Int       Date:  2022-10-07       Impact factor: 5.131

6.  Mesenchymal stem cells have ameliorative effect on the colitis model via Nrf2/HO-1 pathway.

Authors:  Mehmet Fatih Bozkurt; Muhammed Nasir Bhaya; Cengiz Dibekoğlu; Ayberk Akat; Utku Ateş; Oytun Erbaş
Journal:  Acta Cir Bras       Date:  2022-10-10       Impact factor: 1.564

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.